Zevra Therapeutics (NASDAQ:KMPH) Coverage Initiated by Analysts at StockNews.com
Zevra Therapeutics (NASDAQ:KMPH) Coverage Initiated by Analysts at StockNews.com
StockNews.com began coverage on shares of Zevra Therapeutics (NASDAQ:KMPH – Get Rating) in a report published on Friday morning. The brokerage issued a hold rating on the specialty pharmaceutical company's stock.
證券新聞網開始對股票的報導 澤弗拉治療 (納斯達克:KMPH — 獲得評分) 在星期五早上發表的報告中。該經紀公司對該專業製藥公司的股票發出了持有評級。
Separately, Cantor Fitzgerald initiated coverage on Zevra Therapeutics in a research note on Thursday, November 17th. They issued an overweight rating and a $20.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Zevra Therapeutics currently has an average rating of Moderate Buy and an average target price of $17.25.
另外, 坎托·菲茨杰拉德開始覆蓋 Zevra 治療在研究筆記上週四, 11 月 17 日.他們發布了超重評級和 20.00 美元的股票價格目標。一位股票研究分析師將該股票評為持有評級，而四名股票則為該公司分配了買入評級。根據 MarketBeat.com 的數據，澤夫拉治療學目前的平均評級為「中等購買」，平均目標價為 17.25 美元。
Zevra Therapeutics Price Performance
Zevra 治療價格表現
The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.10 and a current ratio of 10.10. The stock has a 50 day moving average of $5.37 and a 200 day moving average of $5.38. Zevra Therapeutics has a 12 month low of $4.00 and a 12 month high of $6.92.
該公司的債務與權益比率為 0.14，快速比率為 10.10，流動比率為 10.10。該股票的日移動平均線為 5.37 美元，而 200 日移動平均線為 5.38 美元。澤弗拉治療學擁有 12 個月低點 4.00 美元，12 個月高點為 6.92 美元。
Insider Transactions at Zevra Therapeutics
Zevra 治療學的內幕交易
In other Zevra Therapeutics news, CEO Richard W. Pascoe acquired 9,500 shares of the business's stock in a transaction dated Friday, January 13th. The shares were purchased at an average cost of $5.44 per share, for a total transaction of $51,680.00. Following the transaction, the chief executive officer now owns 19,973 shares in the company, valued at $108,653.12. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 1.10% of the company's stock.
在其他 Zevra 治療新聞中，首席執行官理查德 ·W· 帕斯科（Richard W· 帕斯科）在 1 月 13 日（星期五）的交易中收購了該業務的 9,500 股股票。這些股份以每股 5.44 美元的平均成本購入，總交易額為 51,680.00 美元。交易後，首席執行官現擁有該公司 19,973 股股份，價值 108,653.12 美元。該收購在與 SEC 提交的文件中披露，該文件可通過以下方式獲得 證券交易所網站。企業內部人士擁有公司股票的 1.10%。
Institutional Investors Weigh In On Zevra Therapeutics
機構投資者權衡 Zevra 治療
Several hedge funds have recently made changes to their positions in the company. Jane Street Group LLC bought a new stake in shares of Zevra Therapeutics during the fourth quarter valued at approximately $147,000. Man Group plc boosted its position in shares of Zevra Therapeutics by 12.9% during the fourth quarter. Man Group plc now owns 33,046 shares of the specialty pharmaceutical company's stock valued at $152,000 after purchasing an additional 3,768 shares in the last quarter. Verition Fund Management LLC bought a new stake in shares of Zevra Therapeutics during the fourth quarter valued at approximately $46,000. Renaissance Technologies LLC boosted its position in shares of Zevra Therapeutics by 12.7% during the fourth quarter. Renaissance Technologies LLC now owns 81,000 shares of the specialty pharmaceutical company's stock valued at $372,000 after purchasing an additional 9,100 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Zevra Therapeutics by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 309,842 shares of the specialty pharmaceutical company's stock valued at $1,422,000 after purchasing an additional 5,190 shares in the last quarter. 19.39% of the stock is currently owned by institutional investors.
幾個對沖基金最近對其在公司的頭寸進行了更改。簡街集團有限責任公司在第四季度購買了 Zevra 治療學股份的新股份，價值約為 147,000 美元。曼恩集團有限公司在第四季度將其在 Zevra 治療學股份中的地位提高了 12.9％。萬安集團在上一季度額外購買 3,768 股股後，擁有該專業製藥公司股票的 33,046 股價值為 152,000 美元。Verition 基金管理有限責任公司在第四季度購買了 Zevra 治療學股份的新股份，價值約為 46,000 美元。文藝復興技術有限責任公司在第四季度將其在 Zevra 治療學的股份中的地位提高了 12.7％。文藝復興技術有限責任公司現在擁有 81,000 股價值的專業製藥公司股票價值 372,000 美元在上一季度額外購買 9,100 股後。最後，Geode 資本管理有限責任公司在第四季度將其在 Zevra 治療的股份中的地位提高了 1.7％。在上個季度額外購買 5,190 股後，奇德資本管理有限責任公司現在擁有該專業製藥公司股票的 309,842 股，價值為 1,422,000 美元。19.39％ 的股票目前由機構投資者擁有。
Zevra Therapeutics Company Profile
Zevra 治療公司簡介
(Get Rating)
(取得評分)
KemPharm, Inc is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy.
KemPharm, Inc 是一家臨床階段的專業製藥公司，從事專有前藥的發現和開發。它通過其稱為配體活化療法的平台技術，專注於治療嚴重的醫療條件，例如注意力缺陷多動障礙，疼痛和其他中樞神經系統疾病。
Featured Stories
特色故事
- Get a free copy of the StockNews.com research report on Zevra Therapeutics (KMPH)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don't Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- 獲取有關澤弗拉治療學（KMPH）的研究報告的免費副本
- 市場節拍週的回顧 — 3 月 13 日 — 3/17
- 這種具有巨大增長前景的小技術正接近買點
- 不要追逐聯邦快遞更高，等待回調
- 3 個防禦性技術投資組合的股票
- 牛奶這些 3 現金奶牛的股息
Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收 Zevra 治療的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Zevra 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。